MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Pearson Syndrome. According to GlobalData, Phase I drugs for Pearson Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MNV-201 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MNV-201 overview
MNV-201 is under development for the treatment of inherited mitochondrial diseases like Leigh syndrome, myelodysplastic syndrome and Pearson syndrome. It is administered by intravenous route. The drug candidate consists of CD34+ cells that are mobilized by granulocyte colony-stimulating factor (G-CSF) enriched with placenta-derived allogeneic mitochondria. The drug candidate is developed based on Mitochondrial Augmentation Therapy (MAT) platform.
Minovia Therapeutics overview
Minovia Therapeutics is a clinical stage company uses mitochondrial cell therapy approach provide therapies to mitochondrial diseases affected people. The company is headquartered in Haifa, Israel.
For a complete picture of MNV-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
